AC Immune reports Q2 EPS (CHF 0.21) vs. (CHF 0.23) last year

Reports Q2 revenue CHF 1.3M vs. CHF 687,000 last year. Dr. Andrea Pfeifer, CEO of AC Immune (ACIU) SA, commented: “AC Immune is continuing to progress toward precision prevention of neurodegenerative diseases as we approach multiple value-inflection points through the rest of 2025 and beyond. Our industry symposium during the AD/PD conference focused on unlocking active immunotherapy for tailored prevention strategies highlighted the momentum of our three active immunotherapies in Phase 2 development. Interim results on ACI-7104.056, our wholly owned a-syn active immunotherapy, reinforced its best-in-class characteristics, showing strong immunogenicity and a favorable safety profile in early Parkinson’s disease. The two partnered programs, ACI-24.060 and ACI-35.030, are also progressing according to plan. In addition, our Morphomer small molecule drugs targeting a-syn and tau and Morphomer-antibody drug conjugates were featured in several presentations at AD/PD 2025. In our exciting early-stage pipeline, ACI-19764, a novel Morphomer small molecule inhibitor of NLRP3, has now entered studies to enable an Investigational New Drug filing. Our strong cash position provides funding into 2027, excluding potential milestone payments, and enables us to advance our robust pipeline focused on precision prevention of neurodegenerative diseases. Further interim results from Part 1 of the VacSYn trial of ACI-7104.056 are expected later this year, and the AD3 cohort in the ABATE trial of ACI-24.060 will reach 12 months of treatment around year end, with interim results thereafter. We also expect to file an IND for ACI-19764 this year.”